Characteristics of physicians who frequently see pharmaceutical sales representatives

Journal of Hospital Marketing and Public Relations

Volumn 19, Issue 1, 2009, Pages 2-14

  Alkhateeb, Fadi M ^a   Khanfar, Nile M ^b   Clauson, Kevin A ^b  

^a Robert C Byrd Center for Pharmacy Education   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Pharmaceutical detailing; Pharmaceutical marketing; Pharmaceutical sales representatives (PSRs); Physician industry relationship

Indexed keywords

ADULT; ARTICLE; DECISION MAKING; FEMALE; HUMAN; MALE; PHYSICIAN; POLICY; PRESCRIPTION; PRIORITY JOURNAL; RURAL AREA; URBAN AREA;

COMMERCE; DATA COLLECTION; DRUG INDUSTRY; FEMALE; HUMANS; INTERINSTITUTIONAL RELATIONS; MALE; MIDDLE AGED; PHYSICIANS;

EID: 61649086942     PISSN: 15390942     EISSN: 15390934     Source Type: Journal    
DOI: 10.1080/15390940802581374     Document Type: Article

References (26)

1. Alkhateeb, F. M., and Doucette, W. R. (2008). Electronic detailing (E-detailing) of pharmaceuticals to physicians: A review. International Journal of Pharmaceutical & Healthcare Marketing 2: 235-245.
2. Andaleeb, S. S., and Tallman, R. F. (1995). Physician attitudes toward pharmaceutical sales representatives. Health Care Manage Rev. 20: 68-76.
3. Bennett, L., Casebeer, L., Kristofco, R., and Collins, B. (2005). Family physicians' information seeking behavior: A survey comparison with other specialties. BMS Medical Informatics and Decision Making 5: 9-14.
4. Bates, A., Bailey, E., and Rajyaguru, I. (2002). Navigating the e-detailing maze. International Journal of Medical Marketing 2: 255-262.
5. Brichacek, A., and Sellers, L. (2001). Flexing their budgets: big pharma spend trends. Pharmaceutical Executives. Available at: http://www.imshealth.com/vgn/images/portal/cit-759/7696bigPharmaSpendTrends.pdf. Last Accessed June 19, 2008.
6. Brontzman, G. L., Mark, D. H. (1993). The effect of resident attitudes on regulatory policies regarding pharmaceutical representative activities. Journal of General Internal Medicine 8(3): 130-134.
7. Chren, M.M., and Landefeld, C. S. (1994). Physicians' behavior and their interactions with drug companies: A controlled study of physicians who requested additions to a hospital drug formulary. Journal of the American Medical Association 271(9): 684-689.
8. Davidson, T., and Sivadas, E. (2004). Details drive success. Marketing Health Services 24: 20-25.
9. Education Council, Residency Training Programme in Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario. (1993). Development of residency program guidelines for interaction with the pharmaceutical industry. Canadian Medical Association Journal 149(4): 405-408.
10. Elling, M. E., Fogle, H. J., McKhann, C. S., and Chris, S. (2002). Making more of pharma's sale force. The McKinsey Quarters 3: 86-95.
11. Ferguson, R. P., Rhim, E., Belizaire, W., Egede, L., Carter, K., and Lansdale, T. (1999). Encounters with pharmaceutical sales representatives among practicing internists. American Journal of Medicine 107(2): 149-152.
12. Gagnon, M. A., and Lexchin, J. (2008). The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine 5(1): 29-33.
13. Gleason, M. (2001). Internet detailing opens the doctor's door. Medical Marketing and Media 36: 80-86.
14. Gleason, M. (2003). Growing market share through more effective physician access. Executive Summary, HyGro Consulting Group, Chicago, IL.
15. Health Strategies Group. (1999). Access to high prescribers: The world of doorknob details. Chicago, IL.
16. Hopper, J. A., Speece, M. W., and Musial, J. L. (1997). Effects of an educational intervention on residents knowledge and attitudes toward interactions with pharmaceutical representatives. Journal of General Internal Medicine 12(10): 639-642.
17. Huston, P. (1993). Doctors want more industry-sponsored meetings. Medical Marketing & Media 28: 48-50;52-53
18. Iyer, S. (2003). Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. University of Iowa, Iowa City.
19. Jordan, H. S., Burke, J. F., Fineberg, H., and Hanley, J. A. (1983). Diffusion of innovations in burn care: Selected findings. Burns, Including Thermal Injury 9(4): 271-279.
20. Levit, K., Smith, C., Cowan, C., Sensenig, A., and Catlin, A. (2004). Health spending rebound continues in 2002. Health Affairs 23: 147-159.
21. Lichstein, P. R. (1992). Impact of pharmaceutical company representatives on internal medicine residency programs. Archives of Internal Medicine 152(5): 1009-1013.
22. McCormick, B. B., Tomlinson, G., Brill-Edwards, P., and Detsky, A. S. (2001). Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. Journal of the American Medical Association 286(16): 1994-1999.
23. Santoro, M., and Gorrie, T. (2005). Ethics and the Pharmaceutical Industry. New York: Cambridge University Press.
24. Sergeant, M. D., Hodgetts, P. G., Godwin, M., Walker, D. M., and McHenry, P. (1996). Interactions with the pharmaceutical industry: A survey of family medicine residents in Ontario. Canadian Medical Association Journal 155(9): 1243-1248.
25. Watkins, C., Moore, L., Harvey, I., Carthy, P., Robinson, E., and Brawn, R. (2003). Characteristics of general practitioners who frequently see drug industry representatives: National cross sectional study. British Medical Journal 326(7400): 1178-1179.
26. Wazana, A. (2000). Physicians and the pharmaceutical industry: Is a gift ever just a gift? Journal of the American Medical Association 283(3): 373-380.